GlassScriptPhysician profile
Sanjay B Dixit
NPI 1194803122
$41,584.78
in general payments reported to CMS, 2019-2025
29 companies · $40.08 in 2025
The $40.08 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,609 · 2020: $3,108 · 2021: $1,340 · 2022: $29K · 2023: $94.44 · 2024: $105 · 2025: $40.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.49 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31,852.81 | 2019-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $6,608.38 | 2019-2022 | |
| Lilly USA, LLC | $737.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $461.39 | 2019-2022 | |
| Cequr Corporation | $224.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.60 | 2019-2022 | |
| Becton, Dickinson and Company | $185.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $113.29 | 2019-2020 | |
| Abbvie INC. | $100.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $98.01 | 2019-2022 | |
| Ibsa Pharma INC. | $95.13 | 2021-2022 | |
| Amgen INC. | $89.97 | 2021-2022 | |
| Insulet Corporation | $86.53 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.14 | 2021-2022 | |
| Abbott Laboratories | $77.38 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $77.23 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $67.93 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $54.87 | 2019 | |
| Dexcom, INC. | $52.16 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $49.06 | 2021-2022 | |
| Corcept Therapeutics | $47.74 | 2019-2020 | |
| Shire North American Group INC | $45.97 | 2019 | |
| Phadia US INC. | $44.23 | 2023 | Immunocap |
| Medtronic Minimed, INC. | $38.35 | 2019 | |
| Xeris Pharmaceuticals, INC. | $30.07 | 2022 | |
| Valeritas, INC. | $20.45 | 2019 | |
| Lifescan, INC. | $18.06 | 2022 | |
| Embecta Corp. | $17.94 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Endo Pharmaceuticals INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.